FreshPatents.com Logo


new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Immunomedics Inc
Immunomedics Inc_20100114
Immunomedics Inc_20100121

Popular
Companies


Web
Adobe patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

Immunomedics Inc patents


      
Recent patent applications related to Immunomedics Inc. Immunomedics Inc is listed as an Agent/Assignee. Note: Immunomedics Inc may have other listings under different names/spellings. We're not affiliated with Immunomedics Inc, we're just tracking patents.

ARCHIVE: New 2015 2014 2013 2012 2011 2010 2009 | Company Directory "I" | Immunomedics Inc-related inventors


Search recent Press Releases: Immunomedics Inc-related press releases
Count Application # Date Immunomedics Inc patents (updated weekly) - BOOKMARK this page
12015011127904/23/15 new patent  Class i anti-cea antibodies and uses thereof
22015009445604/02/15Anthracycline-antibody conjugates for cancer therapy
32015008648203/26/15Dye conjugated peptides for fluorescent imaging
42015005743202/26/15Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
52015003868602/05/15Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
62015001851601/15/15Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
72014037717312/25/14Anti-mucin antibodies for early detection and treatment of pancreatic cancer
82014037717712/25/14Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
92014037728712/25/14Anti-trop-2 antibody-drug conjugates and uses thereof
102014036992712/18/14Camptothecin conjugates of anti-cd22 antibodies for treatment of b cell diseases
112014028686009/25/14Immunoconjugates with an intracellularly-cleavable linkage
122014028686109/25/14Rs7 antibodies
132014023420908/21/14Chimeric and humanized anti-histone antibodies
142014022717808/14/14Humanized anti-hla-dr antibodies
152014022717908/14/14Anti-mucin antibodies for early detection and treatment of pancreatic cancer
162014022718008/14/14Antibody-sn-38 immunoconjugates with a cl2a linker
172014022854108/14/14Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
182014021991408/07/14Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
192014021995608/07/14Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
202014021242507/31/14Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
212014019335907/10/14Ultrafiltration concentration of allotype selected antibodies for small-volume administration
222014017829406/26/14Ultrafiltration concentration of allotype selected antibodies for small-volume administration
232014017006506/19/14Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments
242014015427306/05/14Anthracycline-antibody conjugates for cancer therapy
252014014738205/29/14Immunotherapy of b cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
262014014092405/22/14Humanized l243 antibodies
272014012003505/01/14Rs7 antibodies
282014011286404/24/14Anti-mucin antibodies for early detection and treatment of pancreatic cancer
292014011286504/24/14Anti-cd19 antibodies
302014010581904/17/14In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
312014009925804/10/14Camptothecin-binding moiety conjugates
322014008683003/27/14Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r)
332014008683203/27/14Delivery system for cytotoxic drugs by bispecific antibody pretargeting
342014007962903/20/14Class i anti-cea antibodies and uses thereof
352014005806702/27/14Immunoconjugates with an intracellularly-cleavable linkage
362014004463902/13/14Antibody therapy
372014004464002/13/14Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
382014003754302/06/14Anti-pancreatic cancer antibodies
392014003826102/06/14Compositions and methods of use of immunotoxins comprising ranpirnase (rap) show potent cytotoxic activity
402014003828402/06/14Mammalian cell lines for increasing longevity and protein yield from a cell culture
412014001716801/16/14Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
422014001719701/16/14Anti-cd19 antibodies
432014000407801/02/14Immunoconjugates with an intracellularly-cleavable linkage
442013031582111/28/13Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
452013030917711/21/13In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
462013021656108/22/13Immunoconjugates with an intracellularly-cleavable linkage
472013020935608/15/13Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
482013021104408/15/13Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
492013017749807/11/13Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
502013017752607/11/13Camptothecin conjugates of anti-cd22 antibodies for treatment of b cell diseases
512013017106407/04/13Anti-cd74 immunoconjugates and methods of use
522013017106507/04/13In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
532013017117607/04/13Anthracycline-antibody conjugates for cancer therapy
542013016421406/27/13Antibody-based depletion of antigen-presenting cells and dendritic cells
552013016478306/27/13Mammalian cell lines for increasing longevity and protein yield from a cell culture
562013015669106/20/13Antibody therapy
572013014278706/06/13Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
582013014329606/06/13Delivery system for cytotoxic drugs by bispecific antibody pretargeting
592013012191305/16/13Anti-cd19 antibodies
602013012347305/16/13Bispecific antibody targeting a complement factor or complement regulatory protein
612013009503404/18/13Anti-cd74 immunoconjugates and methods
622013009045804/11/13Immunoconjugates with an intracellularly-cleavable linkage
632013007818203/28/13Structural variants of antibodies for improved therapeutic characteristics
642013007826303/28/13Anti-hla-dr antibodies suppress allogeneic and xenogeneic immune responses to organ transplants
652013007132003/21/13Immunotherapy of autoimmune disorders using antibodies which target b-cells
662013007140603/21/13Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments
672013007265903/21/13Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
682013003986102/14/13Dye conjugated peptides for fluorescent imaging
692013003449202/07/13Class i anti-cea antibodies and uses thereof
702012032856412/27/12Camptothecin-binding moiety conjugates
712012032863412/27/12Immunoconjugates with an intracellularly-cleavable linkage
722012032155312/20/12Ultrafiltration concentration of allotype selected antibodies for small-volume administration
732012028217811/08/12Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
742012027610011/01/12Compositions and methods of use of immunotoxins comprising ranpirnase (rap) show potent cytotoxic activity
752012023095309/13/12Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
762012021496908/23/12Methods and compositions for f-18 labeling of proteins, peptides and other molecules
772012019632608/02/12Mammalian cell lines for increasing longevity and protein yield from a cell culture
782012018954207/26/12Anti-cd19 antibodies
792012018347207/19/12Immunotherapy of b-cell malignancies using anti-cd22 antibodies
802012018355007/19/12Therapeutic using a bispecific antibody
812012014908506/14/12Fusion proteins containing recombinant cytotoxic rnases
822012014137206/07/12Rs7 antibodies
832012014137506/07/12Anti-mucin antibodies for early detection and treatment of pancreatic cancer
842012013492005/31/12Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
852012011455605/10/12Immunotherapy of autoimmune disorders using antibodies which target b-cells
862012010723505/03/12Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
872012008829904/12/12Mammalian cell lines for increasing longevity and protein yield from a cell culture
882012008261704/05/12Immunoconjugates with an intracellularly-cleavable linkage
892012007672703/29/12In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
902012006399303/15/12Therapeutic and diagnostic conjugates for use with multispecific antibodies
912012003979702/16/12Antibody therapy
922012004043102/16/12Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
932012003418502/09/12Anti-cd20 antibodies and fusion proteins therof and methods of use
942011031153112/22/11Immunotherapy of autoimmune disorders using antibodies which target b-cells
952011030563112/15/11Camptothecin conjugates of anti-cd22 antibodies for treatment of b cell diseases
962011030006612/08/11Combination therapy with anti-cd74 antibodies provides enhanced toxicity to malignancies, autoimmune disease and other diseases
972011029351312/01/11Immunoconjugates with an intracellularly-cleavable linkage
982011028691811/24/11Immunotherapy of autoimmune disorders using antibodies which target b-cells
992011028080111/17/11Methods and compositions for f-18 labeling of proteins, peptides and other molecules
1002011027470411/10/11Compositions and methods of use of immunotoxins comprising ranpirnase (rap) show potent cytotoxic activity
1012011025605310/20/11Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to b-cell lymphomas and other diseases
1022011024384110/06/11Antibody-based depletion of antigen-presenting cells and dendritic cells
1032011024454610/06/11Internalizing anti-cd74 antibodies and methods of use
1042011023630409/29/11Structural variants of antibodies for improved therapeutic characteristics
1052011023640409/29/11Methods for protein expression in mammalian cells in serum-free medium
1062011022940709/22/11Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
1072011022364509/15/11Multivalent carriers of bi-specific antibodies
1082011019502308/11/11Internalizing anti-cd74 antibodies and methods of use
1092011018908508/04/11Antibody therapy
1102011018926808/04/11Inhibition of placenta growth factor (plgf) mediated metastasis and/or angiogenesis
1112011017112607/14/11Enhanced cytotoxicity of anti-cd74 and anti-hla-dr antibodies with interferon-gamma
1122011016507207/07/11Detection of early-stage pancreatic adenocarcinoma
1132011016507307/07/11Immunotherapy of b-cell malignancies using anti-cd22 antibodies
1142011011701005/19/11Methods and compositions for administering therapeutic and diagnostic agents
1152011011710505/19/11Method of treating immune disease using b-cell antibodies
1162011011085405/12/11Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
1172011007623303/31/11Delivery system for cytotoxic drugs by bispecific antibody pretargeting
1182011007015503/24/11Anti-cd74 immunoconjugates and methods
1192011007015603/24/11Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
1202011006465303/17/11Class i anti-cea antibodies and uses thereof
1212011005248903/03/11Anti-cd19 antibodies
1222010031116212/09/10Mammalian cell lines for increasing longevity and protein yield from a cell culture
1232010028490611/11/10Internalizing anti-cd74 antibodies and methods of use
1242010027263610/28/10Anti-cd74 immunoconjugates and methods of use
1252010026649610/21/10Anti-cd74 immunoconjugates and methods of use
1262010026649710/21/10Internalizing anti-cd74 antibodies and methods of use
1272010023377909/16/10Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
1282010022688409/09/10Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r)
1292010022117509/02/10Antibody therapy
1302010022117709/02/10Rs7 antibodies
1312010021666208/26/10Inhibition of placenta growth factor (plgf) mediated metastasis and/or angiogenesis
1322010020296108/12/10D-amino acid peptides
1332010019626608/05/10Humanized anti-hla-dr antibodies
1342010019626708/05/10Humanized l243 antibodies
1352010019698908/05/10Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
1362010018964107/29/10Novel strategies for improved cancer vaccines
1372010015880206/24/10Chimeric, human and humanized anti-csap monoclonal antibodies
1382010015880306/24/10Production and use of novel peptide-based agents for use with bi-specific antibodies
1392010013662606/03/10Production and use of novel peptide-based agents for use with bi-specific antibodies
1402010010458904/29/10Immunoconjugates with an intracellularly-cleavable linkage
1412010007484003/25/10Anthracycline-antibody conjugates for cancer therapy
1422010006813603/18/10Anti-cd19 antibodies
1432010004054102/18/10Structural variants of antibodies for improved therapeutic characteristics
1442010003473802/11/10Structural variants of antibodies for improved therapeutic characteristics
1452010001504601/21/10Camptothecin-binding moiety conjugates
1462010001504801/21/10Internalizing anti-cd74 antibodies and methods of use
1472010000885501/14/10Production and use of novel peptide-based agents with bispecific antibodies
1482010000885801/14/10Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
1492009030458012/10/09Anti-pancreatic cancer antibodies
1502009029903312/03/09Methods and compositions for f-18 labeling of proteins, peptides and other molecules
1512009029109311/26/09Immunoconjugates with an intracellularly-cleavable linkage
1522009028575211/19/09Immunotherapy of b cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
1532009027464911/05/09Bispecific antibody point mutations for enhancing rate of clearance
1542009025273110/08/09Multivalent carriers of bi-specific antibodies
1552009025317910/08/09Mammalian cell lines for increasing longevity and protein yield from a cell culture
1562009024613010/01/09Methods and compositions for f-18 labeling of proteins, peptides and other molecules
1572009024613110/01/09Production and use of novel peptide-based agents for use with bi-specific antibodies
1582009024621410/01/09Fusion proteins containing recombinant cytotoxic rnases
1592009023875709/24/09Methods and compositions for administering therapeutic and diagnostic agents
1602009024003709/24/09Humanized antibodies and methods of humanizing antibodies
1612009018597407/23/09Chimeric, human and humanized anti-granulocyte antibodies and methods of use
1622009015516606/18/09Methods and compositions for f-18 labeling of proteins, peptides and other molecules
1632009015525306/18/09Anti-cd20 antibodies and fusion proteins therof and methods of use
1642009011114304/30/09Methods and compositions for mammalian cell lines for transfection and protein expression in serum-free medium
1652009009259804/09/09Antibody therapy
1662010001504801/21/10Internalizing anti-cd74 antibodies and methods of use
1672010000885801/14/10Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules



ARCHIVE: New 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Immunomedics Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Immunomedics Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###

     SHARE